{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"19"}]}],"title":"CrCl< 30 mL/min to CrCl< 30 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"19"}]}],"title":"CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}]}],"title":"CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"CrCl< 30 mL/min to ≥ 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"CrCl≥ 30 but < 50 mL/min to < 30 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"41"}]}],"title":"CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"65"}]}],"title":"CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"2"}]}],"title":"CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"102"}]}],"title":"CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"97"}]}],"title":"CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"CrCl ≥ 80 mL/min to CrCl< 30 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"}]}],"title":"CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"114"},{"groupId":"OG002","value":"121"}]}],"title":"CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min"}],"denoms":[{"counts":[{"groupId":"OG000","value":"494"},{"groupId":"OG001","value":"506"},{"groupId":"OG002","value":"484"}],"units":"Participants"}],"description":"Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation.","groups":[{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.","id":"OG000","title":"Lenalidomide and Low-Dose Dexamethasone (Rd)"},{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.","id":"OG001","title":"Lenalidomide and Dexamethasone Rd18"},{"description":"Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.","id":"OG002","title":"Melphalan + Prednisone + Thalidomide (MPT)"}],"paramType":"NUMBER","populationDescription":"Safety Population with baseline and postbaseline CrCl data.","reportingStatus":"POSTED","timeFrame":"Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm","title":"Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase","type":"SECONDARY","unitOfMeasure":"participants"}